Cabral G, Schoefmann N, Wolff-Winiski B (2025)
CHANGES IN THE PROTEOME INDICATE A SPECIFIC ROLE OF STAT-4 IN MEDIATING THE FIBROBLAST INFLAMMATORY RESPONSE TO CHRONIC WOUND EXUDATE.
Poster at the 35th Conference of the European Wound Management Association, the EWMA - GNEAUPP 2025 CONFERENCE, March 26-28, 2025, Barcelona, Spain
Wolff-Winiski B, Schoefmann N, Doerfler P, Cabral G, Stuetz A (2025)
Identification of AKR101 as potential new drug for chronic wound therapy.
Oral presentation at the 35th Conference of the European Wound Management Association, the EWMA - GNEAUPP 2025 CONFERENCE, March 26-28, 2025, Barcelona, Spain
Chinese patent granted for selected compounds for chronic wound therapy
Patent for selected compounds for chronic wound therapy granted in Singapore
Meet us at 4. WundD.A.CH Kongress 2025 in Freiburg, Germany.
Doerfler P, Schoefmann N, Stuetz A, Wolff-Winiski B (2022)
Development of a “theranostic” assay for chronic wounds and identification of compounds with so far unknown potential for treatment of chronic wounds
Oral presentation at the ÖGMBT 2022 Annual Meeting, Sept 19-22, 2022, in Vienna, Austria
Doerfler P, Schoefmann N, Cabral G, Stuetz A, Wolff-Winiski B (2024)
Identification and characterization of potential wound therapeutics based on a new personalized ex vivo wound model.
Poster at the ETRS-WHS-SKINTERM 2024 Annual Meeting, Sept. 24-27, 2024 in Amersfoort, Netherlands
Cabral G, Doerfler P, Schoefmann N, Stuetz A, Wolff-Winiski B (2023)
Development of personalized treatment for chronic wounds
Oral presentation at the ETRS 2022, Sept. 15-17, 2022, in Lyon, France
Wolff-Winiski B, Doerfler P, Schoefmann N, Cabral G, Stuetz A (2024)
Patient-specific assays to identify and characterize new drugs for chronic wound therapy.
Oral presentation at the EUSAAT Congress 2024, September 18-20, 2024, Linz, Austria
ALTEX Proceedings 12(2), 2024, EUSAAT, p.107.
Japanese patent granted for selected compounds for chronic wound therapy